DA
RARE icon

Duality Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Duality Advisers’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-39,977
Closed -$1.87M – 423
2024
Q1 		$1.87M Buy
39,977
+606
+2% +$28.6K 0.18% 197
2023
Q4 		$1.88M Buy
39,371
+12,333
+46% +$478K 0.2% 183
2023
Q3 		$964K Buy
27,038
+12,715
+89% +$504K 0.12% 302
2023
Q2 		$661K Buy
+14,323
New +$664K 0.08% 349
2022
Q4 		– Sell
-47,879
Closed -$1.98M – 742
2022
Q3 		$1.98M Buy
+47,879
New +$2.46M 0.22% 180

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Duality Advisers's RARE Position: Q2 2024 in Review

Duality Advisers sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 39,977 shares — an estimated $1.87M sold.

Duality Advisers first reported a position in RARE in Q3 2022 and held it in 5 quarters. The position peaked at $1.98M in Q3 2022. 275 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

  • Duality Advisers reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 39,977 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $1.87M.
  • Duality Advisers first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and held it in 5 quarters.
  • Duality Advisers's Ultragenyx Pharmaceutical position peaked at $1.98M in Q3 2022.
  • 275 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.